DOI 10.1186/s12967-026-07678-1
PPM1A dysfunction aggravates DPN pathology through NF-κB/NLRP3/p-tau axis involving Schwann cell/DRG neuron crosstalk.
Аннотация
BACKGROUND
Diabetic peripheral neuropathy (DPN) is a severe diabetic complication with complex pathogenesis. Hyperphosphorylation of tau (p-tau) and neuroinflammation are tightly associated with DPN pathology, although the underlying mechanisms remain obscure.
METHODS
Phosphoproteomics assay with biological verification was performed against the sciatic nerve (SN) tissues from DPN patients and normal individuals to explore the key phosphoprotein(s) involved in DPN pathology. Based on these findings, biological assays including in vivo phosphoprotein-knockdown were then carried out to verify the determined phosphoprotein-mediated mechanisms in DPN pathology against the SN tissues/dorsal root ganglion (DRG) of the model mice.
RESULTS
Protein phosphatase Mg²⁺/Mn²⁺ dependent 1 A (PPM1A) enzyme activity was abnormally reduced in both DPN patients and model mice. Treatment with Miltefosine (MF), a PPM1A activator, effectively improved the DPN-like pathology in mice. PPM1A dysfunction aggravates DPN pathology through NF-κB/NLRP3/p-tau axis involving Schwann cell/DRG neuron crosstalk.
CONCLUSION
Our results highlight the close linkage of PPM1A dysfunction to DPN pathology and suggest that pharmacological activation of PPM1A is a potential therapeutic tactic for DPN, while MF shows promise as a valuable drug lead compound against DPN.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.